Search research articles
Contact Us
Filters
Showing results (31-40 of 212) with videos related to
Page
of 22
Sort By:
Clinical Case Reports
|
April 13, 2022
A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature
Francesca Bacchiarri, Alessandro Gozzetti, Nicola Mondanelli, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
October 30, 2017
Sixth nerve and superior division of third nerve palsy due to intracranial extension of multiple myeloma. A diagnostic challenge and differential diagnosis
Domenica Zaino, Alessandra Rufa, Alessandro Gozzetti, et al.
Cancers
|
July 24, 2021
The Role of Tumor-Associated Macrophages in Hematologic Malignancies
Emanuele Cencini, Alberto Fabbri, Anna Sicuranza, et al.
Anti-Cancer Agents in Medicinal Chemistry
|
September 6, 2016
Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies
Alberto Fabbri, Emanuele Cencini, Alessandro Gozzetti, et al.
Frontiers in Oncology
|
December 15, 2022
"Friends and foes" of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
Paola Pacelli, Donatella Raspadori, Elena Bestoso, et al.
Leukemia Research
|
April 6, 2010
Hyperlipidemia in a myeloma patient after bortezomib treatment
Alessandro Gozzetti, Alberto Fabbri, Marzia Defina, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology
|
June 17, 2020
A <i>BRAF</i>-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin
Alessandro Gozzetti, Vincenzo Sammartano, Francesca Bacchiarri, et al.
Blood Research
|
November 7, 2021
Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?
Emanuele Cencini, Alberto Fabbri, Donatella Raspadori, et al.
British Journal of Haematology
|
March 13, 2016
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to IV bortezomib?
Alessandro Gozzetti, Veronica Candi, Corrado Zuanelli Brambilla, et al.
Cancer Genetics and Cytogenetics
|
July 10, 2003
A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement
Alessandro Gozzetti, Daniela Tozzuoli, Rosaria Crupi, et al.
Page
of 22
Search research articles
Search
Showing results (31-40 of 212) with videos related to
Sort By:
Page
of 22
Clinical Case Reports
|
April 13, 2022
A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature
Francesca Bacchiarri, Alessandro Gozzetti, Nicola Mondanelli, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
October 30, 2017
Sixth nerve and superior division of third nerve palsy due to intracranial extension of multiple myeloma. A diagnostic challenge and differential diagnosis
Domenica Zaino, Alessandra Rufa, Alessandro Gozzetti, et al.
Cancers
|
July 24, 2021
The Role of Tumor-Associated Macrophages in Hematologic Malignancies
Emanuele Cencini, Alberto Fabbri, Anna Sicuranza, et al.
Anti-Cancer Agents in Medicinal Chemistry
|
September 6, 2016
Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies
Alberto Fabbri, Emanuele Cencini, Alessandro Gozzetti, et al.
Frontiers in Oncology
|
December 15, 2022
"Friends and foes" of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
Paola Pacelli, Donatella Raspadori, Elena Bestoso, et al.
Leukemia Research
|
April 6, 2010
Hyperlipidemia in a myeloma patient after bortezomib treatment
Alessandro Gozzetti, Alberto Fabbri, Marzia Defina, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology
|
June 17, 2020
A <i>BRAF</i>-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin
Alessandro Gozzetti, Vincenzo Sammartano, Francesca Bacchiarri, et al.
Blood Research
|
November 7, 2021
Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?
Emanuele Cencini, Alberto Fabbri, Donatella Raspadori, et al.
British Journal of Haematology
|
March 13, 2016
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to IV bortezomib?
Alessandro Gozzetti, Veronica Candi, Corrado Zuanelli Brambilla, et al.
Cancer Genetics and Cytogenetics
|
July 10, 2003
A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement
Alessandro Gozzetti, Daniela Tozzuoli, Rosaria Crupi, et al.
Page
of 22